Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Chronic myeloid leukemia (mmu05220)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Abl1
KLA  ATP  ATP+KLA
 AK083248 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630031E05 product:v-abl Abelson murine leukemia oncogene 1, full insert sequence. [AK083248] KLA 1.07 1.07 .92 1.01 .98 1.07 .98
ATP .98 .99 .94 .90 .99 1.07 1.04
KLA/ATP 1.04 1.01 1.03 .98 .97 .95 .99
Abl1
KLA  ATP  ATP+KLA
 NM_009594 c-abl oncogene 1, receptor tyrosine kinase (Abl1), transcript variant 2, mRNA [NM_009594] KLA .63 .62 .65 .71 .96 1.17 1.05
ATP 1.01 1.16 1.03 1.14 1.12 .98 .98
KLA/ATP .66 .64 .67 .73 .84 .90 1.05
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Araf
KLA  ATP  ATP+KLA
 NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
Bad
KLA  ATP  ATP+KLA
 AK029400 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] KLA 1.15 1.22 1.26 1.31 1.40 1.67 1.59
ATP .95 1.06 1.12 1.06 .78 .89 1.27
KLA/ATP 1.25 1.39 1.33 1.29 1.11 .91 1.38
Bcl2l1
KLA  ATP  ATP+KLA
 NM_009743 Bcl2-like 1 (Bcl2l1), nuclear gene encoding mitochondrial protein, mRNA [NM_009743] KLA .99 1.02 1.10 1.16 1.27 .97 1.05
ATP 1.18 1.42 .81 1.26 1.51 .71 1.67
KLA/ATP 1.21 1.30 .66 1.15 1.31 1.17 1.59
Bcr
KLA  ATP  ATP+KLA
 NM_001081412 breakpoint cluster region homolog (Bcr), mRNA [NM_001081412] KLA 1.00 1.03 1.04 .98 .99 .98 .92
ATP 1.00 1.02 1.06 1.26 1.15 1.09 1.03
KLA/ATP 1.06 1.11 1.08 1.24 1.08 1.04 1.05
BI646741
KLA  ATP  ATP+KLA
 BI646741 gb|BI646741 603279769F1 NCI_CGAP_Mam3 Mus musculus cDNA clone IMAGE:5320025 5, mRNA sequence [BI646741] KLA .55 .54 .47 .54 .65 1.09 1.60
ATP 1.04 .99 .93 1.08 2.49 .79 .88
KLA/ATP .54 .49 .54 .60 1.21 .97 1.54
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Cbl
KLA  ATP  ATP+KLA
 NM_007619 Casitas B-lineage lymphoma (Cbl), mRNA [NM_007619] KLA 1.23 1.22 1.54 1.84 2.25 2.58 2.75
ATP 1.04 1.12 1.07 1.53 1.55 2.12 3.23
KLA/ATP 1.23 1.20 1.22 1.44 1.31 1.88 6.28
Cblb
KLA  ATP  ATP+KLA
 AK045005 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130018P07 product:hypothetical protein, full insert sequence. [AK045005] KLA 1.16 1.11 1.15 1.10 1.16 .98 .93
ATP 1.16 1.23 .98 1.28 1.34 .73 1.55
KLA/ATP 1.26 1.60 1.64 1.23 1.01 .91 1.05
Cblb
KLA  ATP  ATP+KLA
 AK084162 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230004I05 product:unclassifiable, full insert sequence. [AK084162] KLA .97 .98 1.02 1.01 .84 1.02 1.03
ATP 1.03 1.02 .98 1.09 1.05 .96 .96
KLA/ATP 1.07 .95 .91 .98 .98 1.01 1.00
Cblc
KLA  ATP  ATP+KLA
 NM_023224 Casitas B-lineage lymphoma c (Cblc), mRNA [NM_023224] KLA 1.02 .98 1.01 1.02 1.00 .99 1.05
ATP .94 .95 .97 1.04 .99 .97 .99
KLA/ATP 1.00 1.01 .96 .97 .94 .92 .99
Ccnd1
KLA  ATP  ATP+KLA
 S78355 gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] KLA .24 .23 .23 .24 .29 .47 .17
ATP 1.02 1.02 .88 .80 .52 .10 .21
KLA/ATP .27 .23 .22 .24 .27 .25 .14
Cdk4
KLA  ATP  ATP+KLA
 NM_009870 cyclin-dependent kinase 4 (Cdk4), mRNA [NM_009870] KLA .66 .72 .65 .55 .46 .50 .71
ATP 1.03 1.02 .53 .65 .66 .63 .75
KLA/ATP .78 .61 .31 .42 .44 .62 .43
Cdk6
KLA  ATP  ATP+KLA
 AK030810 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830411I20 product:unclassifiable, full insert sequence [AK030810] KLA 1.05 .96 .67 .51 .48 .49 .45
ATP 1.02 .91 .78 .49 .50 .47 .44
KLA/ATP 1.01 .89 .65 .40 .36 .26 .49
Cdk6
KLA  ATP  ATP+KLA
 NM_009873 cyclin-dependent kinase 6 (Cdk6), mRNA [NM_009873] KLA 2.63 2.36 2.14 1.80 1.55 1.32 1.03
ATP 1.11 1.21 1.06 1.23 .94 1.30 2.08
KLA/ATP 2.58 2.69 2.24 2.25 1.38 .85 3.00
Cdkn1a
KLA  ATP  ATP+KLA
 NM_007669 cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM_007669] KLA 4.72 4.90 4.96 3.73 2.11 1.14 1.02
ATP 1.14 1.52 .95 1.69 1.47 2.21 .50
KLA/ATP 5.99 7.08 3.86 6.37 3.00 2.55 2.05
Cdkn1b
KLA  ATP  ATP+KLA
 NM_009875 cyclin-dependent kinase inhibitor 1B (Cdkn1b), mRNA [NM_009875] KLA .81 .84 .84 .91 .93 .88 .97
ATP .99 1.09 .97 1.06 1.48 .94 .91
KLA/ATP .83 .91 1.04 1.36 1.48 1.06 1.09
Cdkn2a
KLA  ATP  ATP+KLA
 NM_009877 cyclin-dependent kinase inhibitor 2A (Cdkn2a), transcript variant 1, mRNA [NM_009877] KLA .95 .95 .86 .96 .91 .90 .75
ATP 1.00 .99 .95 .95 .97 .89 .77
KLA/ATP .95 .96 .92 .94 .90 .85 .76
Chuk
KLA  ATP  ATP+KLA
 NM_007700 conserved helix-loop-helix ubiquitous kinase (Chuk), mRNA [NM_007700] KLA 1.32 1.42 1.41 1.17 1.32 1.22 1.40
ATP 1.22 1.30 1.18 .97 1.02 1.00 1.37
KLA/ATP 1.56 1.61 1.21 1.09 .83 .84 1.17
Crk
KLA  ATP  ATP+KLA
 NM_133656 v-crk sarcoma virus CT10 oncogene homolog (avian) (Crk), mRNA [NM_133656] KLA 1.29 1.32 1.41 1.38 1.75 1.59 1.52
ATP 1.08 1.17 1.01 .93 1.27 2.11 1.70
KLA/ATP 1.37 1.49 1.14 1.09 1.21 1.69 2.32
Crkl
KLA  ATP  ATP+KLA
 NM_007764 v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl), mRNA [NM_007764] KLA 1.85 1.97 2.08 1.73 1.66 1.64 1.36
ATP .97 .94 .78 .74 1.46 1.89 1.46
KLA/ATP 1.92 1.88 1.18 1.44 1.67 2.65 2.72
Ctbp1
KLA  ATP  ATP+KLA
 NM_013502 C-terminal binding protein 1 (Ctbp1), mRNA [NM_013502] KLA .77 .77 .71 .65 .67 .65 .95
ATP .89 .84 .42 .45 .45 .71 .80
KLA/ATP .73 .65 .30 .34 .34 .64 .61
Ctbp2
KLA  ATP  ATP+KLA
 NM_009980 C-terminal binding protein 2 (Ctbp2), mRNA [NM_009980] KLA .59 .57 .49 .44 .44 .60 .85
ATP .91 .87 .75 .79 .72 .89 .96
KLA/ATP .60 .50 .41 .45 .54 .63 .71
E2f1
KLA  ATP  ATP+KLA
 NM_007891 E2F transcription factor 1 (E2f1), mRNA [NM_007891] KLA .41 .44 .42 .41 .48 .77 .90
ATP 1.01 1.09 1.04 1.13 .83 .53 .84
KLA/ATP .44 .44 .52 .50 .49 .46 .85
E2f2
KLA  ATP  ATP+KLA
 NM_177733 E2F transcription factor 2 (E2f2), mRNA [NM_177733] KLA .13 .13 .14 .20 .19 .19 .18
ATP 1.08 .92 1.01 .85 .65 .38 .38
KLA/ATP .13 .13 .21 .20 .32 .24 .26
E2f3
KLA  ATP  ATP+KLA
 AK085296 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630007K21 product:E2F transcription factor 3, full insert sequence. [AK085296] KLA .98 .97 1.02 1.00 .99 .99 .99
ATP .97 1.06 1.03 .98 1.01 .99 1.00
KLA/ATP 1.12 1.14 1.03 .99 .96 .93 .96
E2f3
KLA  ATP  ATP+KLA
 NM_010093 E2F transcription factor 3 (E2f3), mRNA [NM_010093] KLA 1.11 1.09 1.13 1.21 1.47 1.62 1.65
ATP .97 .98 1.08 1.15 1.45 1.73 1.80
KLA/ATP 1.21 1.13 1.07 1.20 1.45 1.56 1.62
Evi1
KLA  ATP  ATP+KLA
 BC076620 ecotropic viral integration site 1, mRNA (cDNA clone IMAGE:30645345), partial cds [BC076620] KLA 1.04 .98 1.05 .96 1.09 1.04 .92
ATP .94 .96 1.11 1.00 1.03 1.08 1.14
KLA/ATP 1.00 .92 1.02 1.12 1.06 1.00 1.08
Evi1
KLA  ATP  ATP+KLA
 NM_007963 ecotropic viral integration site 1 (Evi1), mRNA [NM_007963] KLA .93 .99 1.04 1.02 1.05 1.11 1.10
ATP .96 .96 .98 1.03 1.03 .85 1.02
KLA/ATP 1.04 .95 .97 1.01 1.10 1.09 .99
Gab2
KLA  ATP  ATP+KLA
 NM_010248 growth factor receptor bound protein 2-associated protein 2 (Gab2), mRNA [NM_010248] KLA 1.01 1.04 1.04 1.02 1.12 1.16 1.14
ATP 1.02 1.06 1.00 1.13 1.16 1.19 1.23
KLA/ATP 1.06 1.05 1.03 1.02 1.03 1.04 1.29
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Hdac1
KLA  ATP  ATP+KLA
 U80780 putative histone deacetylase (HD1) mRNA, partial cds [U80780] KLA 2.59 2.39 2.48 2.74 3.36 2.56 1.22
ATP 1.13 1.26 1.18 1.08 .85 1.29 1.15
KLA/ATP 2.15 2.27 2.64 2.57 1.78 1.89 2.31
Hdac2
KLA  ATP  ATP+KLA
 AK051753 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130072G11 product:histone deacetylase 2, full insert sequence [AK051753] KLA .97 .97 .90 .96 1.02 .93 .96
ATP 1.02 1.03 .98 .96 .96 .90 1.05
KLA/ATP 1.00 .96 .87 .99 .92 1.00 .95
Hdac2
KLA  ATP  ATP+KLA
 NM_008229 histone deacetylase 2 (Hdac2), mRNA [NM_008229] KLA 1.27 1.35 1.33 1.18 1.03 .75 1.10
ATP .95 1.05 .79 .96 .82 .85 .81
KLA/ATP 1.28 1.43 .93 1.10 .82 .73 .60
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Ikbkb
KLA  ATP  ATP+KLA
 NM_010546 inhibitor of kappaB kinase beta (Ikbkb), mRNA [NM_010546] KLA 1.88 2.10 2.14 1.83 1.73 1.31 1.19
ATP .81 .74 .55 .49 .59 1.05 .96
KLA/ATP 1.86 1.73 1.39 1.12 .89 1.17 1.24
Ikbkg
KLA  ATP  ATP+KLA
 AK042138 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630062P04 product:unclassifiable, full insert sequence. [AK042138] KLA .92 .87 .78 .78 .87 .88 .62
ATP .84 .71 .80 .50 1.15 2.33 .61
KLA/ATP .72 .69 .74 .48 1.06 1.97 .68
Ikbkg
KLA  ATP  ATP+KLA
 NM_010547 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 1, mRNA [NM_010547] KLA 1.51 1.63 1.74 1.83 1.83 1.73 1.72
ATP .80 .79 .82 .75 .66 2.58 2.37
KLA/ATP 1.43 1.42 1.17 1.04 .71 1.54 3.17
Ikbkg
KLA  ATP  ATP+KLA
 NM_178590 inhibitor of kappaB kinase gamma (Ikbkg), transcript variant 2, mRNA [NM_178590] KLA .84 .93 .86 .91 1.03 .89 .88
ATP 1.03 .98 .68 .56 .51 .93 .68
KLA/ATP .89 .81 .55 .52 .41 .67 .65
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mdm2
KLA  ATP  ATP+KLA
 NM_010786 transformed mouse 3T3 cell double minute 2 (Mdm2), mRNA [NM_010786] KLA 1.77 1.59 1.98 1.51 1.77 1.60 1.77
ATP 1.01 1.21 1.36 3.24 5.04 2.08 1.36
KLA/ATP 1.89 1.86 2.93 5.65 5.98 2.78 2.64
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.22094
6
KLA  ATP  ATP+KLA
 27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.26687
1
KLA  ATP  ATP+KLA
 80978931 Unknown KLA .67 .63 .70 .83 1.66 1.43 1.54
ATP 1.20 1.24 1.22 1.26 1.80 .81 1.02
KLA/ATP .63 .56 .83 1.06 1.26 .70 1.34
Mm.27304
9
KLA  ATP  ATP+KLA
 119672895 Unknown KLA .23 .22 .22 .22 .30 .51 .16
ATP 1.08 1.05 .88 .78 .47 .09 .20
KLA/ATP .28 .22 .21 .24 .26 .22 .12
Mm.30793
2
KLA  ATP  ATP+KLA
 160333363 Unknown KLA .13 .12 .14 .16 .15 .18 .15
ATP .92 .94 1.12 .93 .58 .29 .31
KLA/ATP .11 .11 .18 .20 .28 .20 .19
Mm.4387
KLA  ATP  ATP+KLA
 133892666 Unknown KLA .85 .87 .85 .89 .77 .91 1.18
ATP 1.01 1.01 .87 1.07 .75 .86 .93
KLA/ATP .88 .86 .77 .81 .72 .91 .84
Mm.47351
0
KLA  ATP  ATP+KLA
 162287332 Unknown KLA 4.46 4.82 5.29 4.00 2.26 1.25 1.10
ATP 1.24 1.72 1.02 2.08 1.66 2.53 .55
KLA/ATP 6.11 7.67 4.29 6.99 3.11 2.86 2.30
Mm.56965
KLA  ATP  ATP+KLA
 6679704 Unknown KLA .96 1.05 1.06 1.01 1.05 .99 .98
ATP .95 .99 .93 1.05 .97 .96 1.02
KLA/ATP .95 1.01 1.03 1.02 .98 .98 .98
Mm.81698
KLA  ATP  ATP+KLA
 158937287 Unknown KLA .95 1.02 1.04 .98 1.01 1.04 1.08
ATP 1.00 1.03 .97 1.00 1.03 .98 .96
KLA/ATP 1.07 1.00 .94 .98 1.03 1.05 .97
Myc
KLA  ATP  ATP+KLA
 NM_010849 myelocytomatosis oncogene (Myc), mRNA [NM_010849] KLA .38 .31 .45 .45 .49 .35 .33
ATP 1.05 1.09 1.72 4.41 1.28 .45 .76
KLA/ATP .37 .30 .44 1.23 .34 .17 .19
Nfkb1
KLA  ATP  ATP+KLA
 BC050841 nuclear factor of kappa light chain gene enhancer in B-cells 1, p105, mRNA (cDNA clone IMAGE:6392793), complete cds. [BC050841] KLA 5.81 4.96 4.77 3.21 3.37 2.00 1.71
ATP 1.39 1.52 3.25 12.63 13.64 4.80 1.08
KLA/ATP 7.21 8.69 19.53 23.93 11.70 2.85 2.01
Nfkb1
KLA  ATP  ATP+KLA
 M57999 gb|Mouse transcription factor NF-kappa-B DNA binding subunit mRNA, complete cds. [M57999] KLA 8.55 7.87 7.35 6.13 3.51 1.85 1.38
ATP .98 .96 1.21 3.06 5.29 4.67 .69
KLA/ATP 7.32 7.20 8.71 10.82 5.55 2.77 1.54
Nfkbia
KLA  ATP  ATP+KLA
 NM_010907 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (Nfkbia), mRNA [NM_010907] KLA 18.65 18.46 13.63 17.88 14.25 9.17 7.92
ATP .91 1.09 7.11 32.39 17.44 10.49 1.72
KLA/ATP 15.57 17.66 15.73 23.91 13.83 10.73 9.48
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Ptpn11
KLA  ATP  ATP+KLA
 NM_001109992 protein tyrosine phosphatase, non-receptor type 11 (Ptpn11), transcript variant 2, mRNA [NM_001109992] KLA 1.52 1.71 1.59 1.78 1.62 1.57 1.35
ATP 1.04 .93 .86 .79 1.09 1.95 1.90
KLA/ATP 1.59 1.61 1.45 1.11 1.18 1.82 3.02
Ptpn11
KLA  ATP  ATP+KLA
 NM_011202 protein tyrosine phosphatase, non-receptor type 11 (Ptpn11), transcript variant 1, mRNA [NM_011202] KLA 1.32 1.28 1.17 1.21 1.18 1.06 1.05
ATP .97 .77 .71 .56 .90 1.27 1.04
KLA/ATP 1.22 1.21 1.02 .70 .96 1.06 .94
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rb1
KLA  ATP  ATP+KLA
 NM_009029 retinoblastoma 1 (Rb1), mRNA [NM_009029] KLA .67 .60 .55 .51 .46 .75 .79
ATP 1.04 1.01 1.12 .86 .59 .43 .76
KLA/ATP .64 .59 .58 .46 .36 .30 .65
Rela
KLA  ATP  ATP+KLA
 NM_009045 v-rel reticuloendotheliosis viral oncogene homolog A (avian) (Rela), mRNA [NM_009045] KLA 2.05 2.05 2.07 1.75 1.83 1.58 1.33
ATP 1.03 1.08 1.10 1.44 1.61 2.48 1.05
KLA/ATP 2.17 2.27 2.05 2.47 1.93 2.35 2.02
Runx1
KLA  ATP  ATP+KLA
 NM_001111023 runt related transcription factor 1 (Runx1), transcript variant 3, mRNA [NM_001111023] KLA 1.14 1.21 1.40 1.59 1.67 1.51 1.33
ATP 1.02 1.33 1.55 2.35 2.05 1.69 1.70
KLA/ATP 1.18 1.43 1.51 2.75 2.38 1.88 2.62
Runx1
KLA  ATP  ATP+KLA
 NM_009821 runt related transcription factor 1 (Runx1), transcript variant 4, mRNA [NM_009821] KLA .74 .75 .93 1.11 1.15 .87 .89
ATP 1.23 1.19 1.06 1.78 1.35 .47 .76
KLA/ATP .77 .76 .74 1.41 1.55 .48 .61
Shc1
KLA  ATP  ATP+KLA
 NM_011368 src homology 2 domain-containing transforming protein C1 (Shc1), transcript variant 2, mRNA [NM_011368] KLA .88 .87 .86 .83 1.09 1.11 1.12
ATP 1.04 1.25 .85 1.17 .93 1.16 1.00
KLA/ATP .93 .96 .62 .96 .75 1.25 1.19
Shc2
KLA  ATP  ATP+KLA
 NM_001024539 src homology 2 domain-containing transforming protein C2 (Shc2), mRNA [NM_001024539] KLA 1.19 1.25 1.22 1.16 1.15 1.14 .98
ATP 1.04 1.14 1.15 1.53 1.29 1.06 1.09
KLA/ATP 1.26 1.24 1.26 1.49 1.31 1.30 1.30
Shc3
KLA  ATP  ATP+KLA
 NM_009167 src homology 2 domain-containing transforming protein C3 (Shc3), mRNA [NM_009167] KLA 1.00 .98 1.06 1.06 1.12 1.08 1.04
ATP .99 1.02 1.00 1.05 1.00 1.08 1.08
KLA/ATP 1.08 1.06 1.01 1.06 1.03 1.12 1.41
Shc4
KLA  ATP  ATP+KLA
 NM_199022 SHC (Src homology 2 domain containing) family, member 4 (Shc4), mRNA [NM_199022] KLA 1.03 1.03 1.01 1.06 1.09 1.03 1.06
ATP .99 1.00 1.03 1.02 1.04 1.04 1.01
KLA/ATP .98 .97 1.06 1.05 1.00 1.00 1.14
Smad3
KLA  ATP  ATP+KLA
 NM_016769 MAD homolog 3 (Drosophila) (Smad3), mRNA [NM_016769] KLA .64 .60 .57 .64 .70 1.25 1.52
ATP 1.02 1.02 .84 1.21 2.42 .90 1.19
KLA/ATP .64 .60 .65 .66 1.29 1.26 2.26
Smad4
KLA  ATP  ATP+KLA
 NM_008540 MAD homolog 4 (Drosophila) (Smad4), mRNA [NM_008540] KLA 1.11 1.11 1.13 1.09 1.02 .98 1.08
ATP 1.00 1.04 .92 .76 1.67 1.44 .92
KLA/ATP 1.09 1.01 .87 .89 1.64 1.43 .99
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Stat5a
KLA  ATP  ATP+KLA
 NM_011488 signal transducer and activator of transcription 5A (Stat5a), mRNA [NM_011488] KLA 8.23 8.24 6.89 4.88 4.35 1.98 1.01
ATP 1.07 1.14 1.07 1.26 3.23 3.14 1.52
KLA/ATP 8.70 9.53 7.33 6.68 4.32 2.73 1.72
Stat5b
KLA  ATP  ATP+KLA
 AK137889 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130035C01 product:unclassifiable, full insert sequence. [AK137889] KLA 1.10 1.01 .98 .90 1.03 .93 .88
ATP .90 .87 .61 .69 1.01 .97 .89
KLA/ATP 1.12 1.00 .87 .85 .95 1.07 .83
Stat5b
KLA  ATP  ATP+KLA
 NM_011489 signal transducer and activator of transcription 5B (Stat5b), transcript variant 1, mRNA [NM_011489] KLA 2.91 2.81 3.42 2.69 2.23 1.95 1.32
ATP .99 1.04 1.16 .97 1.00 1.84 2.09
KLA/ATP 2.96 3.05 3.17 2.99 1.86 1.87 3.40
Tgfb1
KLA  ATP  ATP+KLA
 NM_011577 transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] KLA .87 .89 .90 .70 .83 .77 1.12
ATP 1.20 1.41 .80 1.49 1.11 .93 .99
KLA/ATP 1.10 1.20 .53 1.05 .66 .85 .90
Tgfb2
KLA  ATP  ATP+KLA
 NM_009367 transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] KLA 1.01 .91 .98 .98 .92 1.19 .96
ATP .99 1.03 1.00 1.02 .99 1.07 .93
KLA/ATP 1.02 .99 1.03 .98 1.04 1.06 .96
Tgfb3
KLA  ATP  ATP+KLA
 NM_009368 transforming growth factor, beta 3 (Tgfb3), mRNA [NM_009368] KLA .67 .64 .58 .56 .49 .52 .61
ATP .90 .92 1.33 1.08 .78 .65 .74
KLA/ATP .58 .60 .74 .61 .76 1.36 1.51
Tgfbr1
KLA  ATP  ATP+KLA
 NM_009370 transforming growth factor, beta receptor I (Tgfbr1), mRNA [NM_009370] KLA .73 .74 .59 .54 .52 .64 .84
ATP .99 1.12 .99 1.16 1.22 .84 .93
KLA/ATP .75 .78 .58 .64 .62 .59 .77
Tgfbr2
KLA  ATP  ATP+KLA
 AK090393 10 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:G630098D03 product:transforming growth factor, beta receptor II, full insert sequence. [AK090393] KLA .98 .89 1.00 .96 .94 1.00 .92
ATP .99 .99 .90 .94 .93 .96 1.02
KLA/ATP .92 .96 .98 .98 .98 .95 1.01
Tgfbr2
KLA  ATP  ATP+KLA
 NM_009371 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, mRNA [NM_009371] KLA .55 .50 .58 .50 .52 .55 .44
ATP .98 .75 .50 .32 .41 .29 .50
KLA/ATP .59 .45 .32 .23 .31 .27 .25
Tgfbr2
KLA  ATP  ATP+KLA
 NM_029575 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 2, mRNA [NM_029575] KLA .95 .93 .99 .95 .88 1.02 .82
ATP .87 .93 .84 .84 .74 .72 1.00
KLA/ATP .89 .85 .83 .85 .76 .80 .79
Trp53
KLA  ATP  ATP+KLA
 NM_011640 transformation related protein 53 (Trp53), mRNA [NM_011640] KLA 1.25 1.37 1.11 .86 .72 .71 .95
ATP 1.15 1.32 .90 1.85 1.26 .68 .70
KLA/ATP 1.66 1.49 .80 1.76 .81 .65 .74